Environmental Impact

Clinigen have continued to capture UK emissions as required by the SECR regulations that came into play on 1 April 2019. The collection and creation of the SECR report was facilitated externally by TEAM (Energy Auditing Agency Limited).

The SECR report covers Scope 1 direct emissions, which includes company-owned vehicles, Scope 2 indirect emissions from electricity purchased and Scope 3 emissions from private vehicles for business use. The SECR report matches the financial year for the year ended 30 June 2021.

Using the latest figures provided by the Department for Business, Energy and Industrial Strategy and the Department for Environment, Food and Rural Affairs, TEAM converted the data into tonnes of carbon dioxide equivalent (‘tonnes of CO2e’) and categorised into Scope 1, Scope 2 and Scope 3 emissions. The results are shown below.

The intensity measure variable that the Group has used is total carbon dioxide equivalent emissions (tonnes) per £m of turnover (using the turnover from the previous financial year ending June 2020).

This is considered to be the best metric to alleviate any skew in the data as a result of the unprecedented impact of COVID-19.

Furthermore, if the consumption increases due to an increase in business operation, i.e. generates more emissions and turnover during subsequent years, this metric allows for a good comparison across the years to determine whether the energy performance and carbon savings of the Group have improved.

The result for the year ending 30 June 2021 is an intensity ratio of 0.49 tonnes of CO2e per £m of turnover (FY2020: 1.49 tonnes).

During FY2022 Clinigen have set ourselves the goal of capturing and reporting global emissions and wastage data which will be reported in FY2022 results. This data will be used to set global environmental objectives and initiatives.

In FY2022 we will also be reporting utilising the TCFD disclosure. Clinigen have also completed a CDP disclosure as well as registered on EcoVardis, both of which giver greater transparency to all our stakeholders on the impact we have on the environment and the measures put in place to reduce that impact.

During the year Clinigen put in place a number of initiatives to reduce our impact on the environment such as converting to reusable plastic totes across some of our US hubs and in April 2021 we announced the launch of our Foscavir Infusion Bags in the USA.

The launch of an IV bag presentation, which replaced glass vials, will result in lighter weight transportation and ultimately a reduced carbon footprint during transportation. We also continue to promote recycling and waste disposal throughout the Group through education and audit through our Environmental Management System.